NO314533B1 - Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes - Google Patents

Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes Download PDF

Info

Publication number: NO314533B1
Authority: NO; Norway
Prior art keywords: toremifene; treatment; lpr; mice; acceptable salt
Prior art date: 1992-10-27

Application number

NO19951596A

Other languages

English (en)

Norwegian (no)

Other versions

NO951596D0 (no

NO951596L (no

Inventor

Junpei Itoh

Osamu Miyazaki

Hisao Ekimoto

Michinori Koyama

Tetsushi Saino

Lauri Kangas

Anni Warri

Christer Granberg

Original Assignee

Orion Yhtymae Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-27

Filing date

1995-04-26

Publication date

2003-04-07

1995-04-26 Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy

1995-04-26 Publication of NO951596D0 publication Critical patent/NO951596D0/no

1995-04-26 Publication of NO951596L publication Critical patent/NO951596L/no

2003-04-07 Publication of NO314533B1 publication Critical patent/NO314533B1/no

Links

150000003839 salts Chemical class 0.000 title claims abstract description 10
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 title claims description 15
229960005026 toremifene Drugs 0.000 title claims description 14
201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 10
239000003814 drug Substances 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title claims description 3
208000023275 Autoimmune disease Diseases 0.000 abstract description 10
229940046836 anti-estrogen Drugs 0.000 abstract description 10
230000001833 anti-estrogenic effect Effects 0.000 abstract description 10
239000000328 estrogen antagonist Substances 0.000 abstract description 10
239000003862 glucocorticoid Substances 0.000 abstract description 8
238000002360 preparation method Methods 0.000 abstract description 8
241000699670 Mus sp. Species 0.000 description 28
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 22
229960004167 toremifene citrate Drugs 0.000 description 22
241001465754 Metazoa Species 0.000 description 11
230000000694 effects Effects 0.000 description 9
206010018364 Glomerulonephritis Diseases 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000003637 steroidlike Effects 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 6
229940079593 drug Drugs 0.000 description 6
229960005205 prednisolone Drugs 0.000 description 6
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
206010040628 Sialoadenitis Diseases 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
208000001050 sialadenitis Diseases 0.000 description 5
230000001363 autoimmune Effects 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
230000008961 swelling Effects 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000008021 deposition Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
108010052621 fas Receptor Proteins 0.000 description 3
102000018823 fas Receptor Human genes 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
239000003826 tablet Substances 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000009472 formulation Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
230000001629 suppression Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010071155 Autoimmune arthritis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000725101 Clea Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
208000012761 aggressive behavior Diseases 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
SBVVUEPVKSOHHY-UHFFFAOYSA-N n,n-dimethyl-1-phenoxyethanamine Chemical compound CN(C)C(C)OC1=CC=CC=C1 SBVVUEPVKSOHHY-UHFFFAOYSA-N 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960003454 tamoxifen citrate Drugs 0.000 description 1
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

NO19951596A 1992-10-27 1995-04-26 Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes NO314533B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP31077292		1992-10-27
PCT/JP1993/001543 WO1994009764A1 (en)	1992-10-27	1993-10-26	Use of non steroidal anti estrogens for autoimmune diseases

Publications (3)

Publication Number	Publication Date
NO951596D0 NO951596D0 (no)	1995-04-26
NO951596L NO951596L (no)	1995-04-26
NO314533B1 true NO314533B1 (no)	2003-04-07

Family

ID=18009292

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19951596A NO314533B1 (no)	1992-10-27	1995-04-26	Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes
NO20025179A NO317544B1 (no)	1992-10-27	2002-10-28	Produkter for autoimmune sykdommer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20025179A NO317544B1 (no)	1992-10-27	2002-10-28	Produkter for autoimmune sykdommer

Country Status (12)

Country	Link
US (3)	US6355688B1 (de)
EP (2)	EP0667768B1 (de)
KR (1)	KR100303634B1 (de)
CN (1)	CN1053337C (de)
AT (1)	ATE177008T1 (de)
AU (1)	AU5286693A (de)
DE (1)	DE69323759T2 (de)
DK (1)	DK0667768T3 (de)
ES (1)	ES2128441T3 (de)
GR (1)	GR3029682T3 (de)
NO (2)	NO314533B1 (de)
WO (1)	WO1994009764A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US5847007A (en) *	1993-05-13	1998-12-08	Neorx Corporation	Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5521198A (en)	1993-12-21	1996-05-28	Eli Lilly And Company	Methods of inhibiting autoimmune diseases
CA2280181A1 (en) *	1997-02-09	1998-08-13	Pharmos Corporation	Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
WO1998039755A2 (en)	1997-03-06	1998-09-11	Nashua Corporation	Display with polarisation-maintaining diffusing sheet
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO2001012206A2 (de) *	1999-08-13	2001-02-22	Heinrich Wieland	Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
US7069444B2 (en) *	2002-01-25	2006-06-27	Brent A. Lowensohn	Portable wireless access to computer-based systems
WO2009149081A1 (en) *	2008-06-02	2009-12-10	Novelmed Therapeutics, Inc.	Method for treating inflammatory conditions
AU2010210344B2 (en)	2009-02-09	2016-02-25	Swimc Llc	In-store tintable non-infrared-absorptive paint and stain system
ES2675093T3 (es)	2009-02-09	2018-07-06	Valspar Sourcing, Inc.	Sistema de pintura y tintura no absorbentes de los infrarrojos y teñibles en tienda
US20130102216A1 (en)	2010-07-01	2013-04-25	Valspar Sourcing, Inc.	Infrared-reflective two-part coating composition
CN102942827A (zh)	2010-10-20	2013-02-27	威士伯采购公司	具有改善耐湿性和耐热性的水基涂料体系
RU2572504C1 (ru) *	2013-12-26	2016-01-10	Андрей Константинович Иорданишвили	Способ лечения лучевой сиалоаденопатии
US11077597B2 (en)	2016-02-23	2021-08-03	Moistureshield, Inc.	Compositions and methods for reducing the surface temperature of composite articles
AU2018205039B2 (en)	2017-01-01	2022-09-22	Moistureshield, Inc.	Methods for coating composite articles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU172948B (hu)	1976-02-05	1979-01-28	Gyogyszerkutato Intezet	Sposob poluchenija osnovnykh proizvodnykh trifenil-alkenov
DE2860900D1 (en)	1977-08-22	1981-11-05	Ici Plc	Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de)	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
GB2126576B (en) *	1982-06-25	1985-06-19	Farmos Group Limited	Alkane and alkene derivatives
FI67538C (fi)	1982-05-27	1985-04-10	Farmos Oy	Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten
US5348729A (en) *	1988-11-30	1994-09-20	The United States Of America As Represented By The Department Of Health And Human Services	Evaluative means for detecting inflammatory reactivity
US4990538A (en) *	1989-08-23	1991-02-05	Harris Adrian L	Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
JPH04312526A (ja) *	1991-04-09	1992-11-04	Fujisawa Pharmaceut Co Ltd	骨疾患治療剤

1993
- 1993-10-26 DK DK93923058T patent/DK0667768T3/da active
- 1993-10-26 EP EP93923058A patent/EP0667768B1/de not_active Expired - Lifetime
- 1993-10-26 EP EP96119031A patent/EP0776661A1/de not_active Withdrawn
- 1993-10-26 WO PCT/JP1993/001543 patent/WO1994009764A1/en not_active Ceased
- 1993-10-26 KR KR1019930022299A patent/KR100303634B1/ko not_active Expired - Fee Related
- 1993-10-26 AU AU52866/93A patent/AU5286693A/en not_active Abandoned
- 1993-10-26 AT AT93923058T patent/ATE177008T1/de not_active IP Right Cessation
- 1993-10-26 DE DE69323759T patent/DE69323759T2/de not_active Expired - Fee Related
- 1993-10-26 ES ES93923058T patent/ES2128441T3/es not_active Expired - Lifetime
- 1993-10-27 CN CN93120398A patent/CN1053337C/zh not_active Expired - Fee Related
1995
- 1995-04-26 NO NO19951596A patent/NO314533B1/no unknown
1999
- 1999-03-12 GR GR990400766T patent/GR3029682T3/el unknown
2000
- 2000-03-01 US US09/516,435 patent/US6355688B1/en not_active Expired - Fee Related
2001
- 2001-07-16 US US09/906,169 patent/US6387958B1/en not_active Expired - Fee Related
2002
- 2002-01-10 US US10/044,064 patent/US6458848B1/en not_active Expired - Fee Related
- 2002-10-28 NO NO20025179A patent/NO317544B1/no unknown

Also Published As

Publication number	Publication date
NO951596D0 (no)	1995-04-26
EP0667768A1 (de)	1995-08-23
CN1100930A (zh)	1995-04-05
KR100303634B1 (ko)	2001-11-22
NO20025179D0 (no)	2002-10-28
KR940008677A (ko)	1994-05-16
WO1994009764A1 (en)	1994-05-11
US6355688B1 (en)	2002-03-12
DE69323759D1 (de)	1999-04-08
NO951596L (no)	1995-04-26
EP0776661A1 (de)	1997-06-04
ES2128441T3 (es)	1999-05-16
US6387958B1 (en)	2002-05-14
US6458848B1 (en)	2002-10-01
DE69323759T2 (de)	1999-07-22
AU5286693A (en)	1994-05-24
NO20025179L (no)	1995-04-26
CN1053337C (zh)	2000-06-14
NO317544B1 (no)	2004-11-08
EP0667768B1 (de)	1999-03-03
US20020107231A1 (en)	2002-08-08
ATE177008T1 (de)	1999-03-15
DK0667768T3 (da)	1999-09-27
GR3029682T3 (en)	1999-06-30

Publication	Publication Date	Title
NO314533B1 (no)	2003-04-07	Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes
TWI389683B (zh)	2013-03-21	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JPH05507697A (ja)	1993-11-04	臓器移植拒絶反応の治療
JP2009527465A (ja)	2009-07-30	筋骨格障害およびそれに関連する症状の処置のための方法、組成物およびキット
CN105263579B (zh)	2020-01-10	左西替利嗪和孟鲁司特在治疗血管炎中的用途
JP2016196473A (ja)	2016-11-24	ラキニモドを用いるループス関節炎の治療
Linton et al.	1967	Methods of forced diuresis and its application in barbiturate poisoning
Van der Horst-Bruinsma et al.	2002	Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs
CN110167538A (zh)	2019-08-23	用于治疗心血管疾病的方法
HU215959B (hu)	1999-03-29	Eljárás 5-metil-izoxazol-4-karbonsav-anilideket vagy 2-hidroxi-etilidén ciano-ecetsav-anilideket tartalmazó, szembetegségek kezelésére helyileg alkalmazható gyógyszerkészítmények előállítására
JP2022534826A (ja)	2022-08-04	炎症性腸疾患及びその腸管外発現の処置のためのアドレナリン作動性β２受容体アゴニストのＲ－エナンチオマーの新たな使用
RU2322238C2 (ru)	2008-04-20	Лечение ревматоидного артрита
JP2017525719A (ja)	2017-09-07	関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用
US5886049A (en)	1999-03-23	Remedy for autoimmune diseases
US20200170990A1 (en)	2020-06-04	Method for treating schnitzler's syndrome
CA2148006C (en)	2006-07-18	Use of non-steroidal antiestrogens for autoimmune diseases
JPS624229A (ja)	1987-01-10	鎮痛及び消炎作用を有する医薬
Carey et al.	1982	Transient hypereosinophilia in the infant of a mother with hypereosinophilic syndrome
CA2569479A1 (en)	2006-02-09	Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
CN102614180A (zh)	2012-08-01	伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
JP3006695B2 (ja)	2000-02-07	腫瘍壊死因子産生促進剤
WO2026052723A1 (en)	2026-03-12	Givinostat hydrochloride monohydrate for use in treating muscular dystrophy
US20090209503A1 (en)	2009-08-20	Colonic delivery therapeutic agents for inflammatory bowel disease
WO2008126094A1 (en)	2008-10-23	Treatment of myocarditis using fts
KR20250034999A (ko)	2025-03-11	만성 이식편대숙주병의 치료를 위한 벨루모수딜의 투여 방법